STOCK TITAN

Crescent Biopharma: Vestal Point reports 8.1% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Crescent Biopharma, Inc. (CBIO) is the issuer whose ordinary shares are covered by an amended ownership report from Vestal Point Capital, LP and Ryan Wilder. Each reports beneficial ownership of the same 3,000,000 shares, or 8.1% of the class; these are not separate holdings to be added together. Both report shared voting and dispositive power over 3,000,000 shares. The Vestal Point Fund and Account directly holds the shares and has the right to receive or direct dividends and proceeds from their sale. The 8.1% calculation uses 37,143,940 ordinary shares outstanding as of July 27, 2026, as reported in the company’s quarterly report for the period ended June 30, 2026.

Beneficially owned 3,000,000 ordinary shares Each reporting person reports the same share position.
Percent of class 8.1% Reported by each reporting person.
Ordinary shares outstanding 37,143,940 shares As of July 27, 2026; used to calculate the reported percentage.
beneficially owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 3,000,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 3,000,000.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CBIO shares did Vestal Point report?

Vestal Point Capital, LP and Ryan Wilder each reported beneficial ownership of the same 3,000,000 ordinary shares, representing 8.1% of the class.

Who are the CBIO 13G/A reporting persons?

The reporting persons are Vestal Point Capital, LP, the investment adviser to a fund and managed account, and Ryan Wilder, its Chief Investment Officer and Managing Partner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G2545C104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Vestal Point Capital, LP
Signature:/s/ Ryan Wilder
Name/Title:By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Date:11/16/2026
Ryan Wilder
Signature:/s/ Ryan Wilder
Name/Title:Ryan Wilder, Individually
Date:11/16/2026

Keep reading